Table 2.
Clinical trials of ASI in advanced CRC
| Ref | Vaccine | Adjuvant | Route | Patients | CR+PR | MR | SD |
|---|---|---|---|---|---|---|---|
| [27] | Anti-Id 3H1 | i.c | AH | 23 | 0 | 0 | NR |
| [28] | CEA/HbsAg-CMV | i.m | HBsAg | 17 | 0 | 0 | 0 |
| [29] | DC-CEA peptid | i.v | No | 10 | 1 | 1 | 2 |
| [30] | ALVAC(CEA-B7.1) | i.m | ALVAC/B7.1 | 13 | 0 | 0 | 2 |
| [31] | DC-CEA peptid | i.v | No | 7 | 0 | 0 | 1 |
| [32] | Auto-tumor | i.d | NDV | 13 | 4 | 0 | 8 |
| [33] | DC-CEA peptid | i.t | No | 10 | 0 | 0 | 2 |
| [34] | Virus CEA | s.c | GM-CSF\IL-2 | 11 | 0 | 0 | NI |
| [35] | Virus CEA | i.d/s.c | Tricom/GM-CSF | 35 | 0 | 0 | 14 |
| [36] | DC-CEA peptid | s.c | No | 7 | 0 | 0 | 2 |
| [37] | SART3 peptide | s.c | IFA | 12 | 0 | 0 | 1 |
| [38] | DC-CEA transfected | i.v+id | IL-2 | 11 | 0 | 0 | 0 |
| [39] | DC-CEA peptid | s.c+id | Tricom | 11 | 0 | 0 | 6 |
| [40] | DC + tumor RNA | i.v | KLH | 15 | 0 | 0 | 0 |
| [41] | DC+MAGE3 peptide | i.v | No | 3 | 0 | 1 | 0 |
| [42] | SART-IcK-CyB multi peptide | s.c | Montanideisa-51 | 10 | 0 | 1 | 1 |
| [43] | Survive peptide | s.c | No | 17 | 0 | 1 | 3 |
| [44] | DC + CEA peptide | s.c/i.d | No | 11 | 0 | 0 | 3 |
| [45] | ALVAC expressing CEA+B7.1 | i.d | B7.1 | 28 | 0 | 0 | 7 |
| [46] | Autologous hemoderivative | s.c | GM-CSF | 50 | 0 | 0 | 26 |
| [47] | DC+allogeneic tumor cell lysate | i.d | No | 17 | 0 | 0 | 4 |
| [48] | TroVax | i.m | MVA | 17 | 0 | 0 | 5 |
| [49] | P53-SLP | s.c | No | 10 | 0 | 0 | 4 |
| [50] | tumor lysate pulsed-Dc | i.t | THI | 8 | 0 | 0 | 4 |
| [51] | Aex+GM-CSF | s.c | GM-CSF | 20 | 0 | 1 | 1 |
| [52] | DC+MHC-I peptide | i.d | IFN-[r]/GM-CSF | 11 | 0 | 0 | 0 |
| [53] | Glutaraldehyde-fixed HUVECs | i.d | No | 3 | 0 | 0 | 0 |
| [54] | Xenogenic polyantigenic vaccine | s.c | IL-2 | 37 | 2 | 10 | 11 |
| [55] | Oncolytic poxvirus JX-594 | PEIT | GM-CSF | 4 | 0 | 0 | 3 |
| [56] | MIDGE | s.c | d-SLIM | 10 | 2 | 1 | 2 |
| [57] | ALVAC-p53 | i.v | ALVAC | 16 | 0 | 0 | 1 |
| [58] | ONYX-015 adevirus | i.v | No | 18 | 0 | 0 | 7 |
| [59] | TNFa AutoVaccIne | i.m | AH | 33 | 2 | 0 | 7 |
| [60] | rF-CEA-TRICOM | i.d | B7.1 | 11 | 0 | 1 | 4 |
| [61] | CEA alt-plused DC | iv | No | 7 | 0 | 0 | 1 |
| [62] | DC-CEA peptid | i.t | IL-4/GM-CSF | 10 | 0 | 0 | 2 |
| [63] | Murine monoclonal CEA-antibody | i.d | AH | 15 | 0 | 0 | 1 |
| [64] | Ep-CAM protein | s.c | MPL/GM-CSF | 11 | 0 | 0 | 3 |
| [65] | Vaccine virus expressing CEA | i.d/s.c | No | 20 | 0 | 0 | 2 |
| [66] | DC + CEA peptide | i.v/i.d | IL-2 | 11 | 0 | 0 | 0 |
| [67] | Antibody SCV 106 mimicking 17-1A | s.c | AH | 21 | 0 | 0 | 0 |
| [68] | Autologous tumor | s.c | Fibroblasts/IL-2 | 10 | 0 | 0 | 1 |
| [69] | retroviral vector- IL-2 allogeneic tumor cells + IL-1a | i.d | DETOX/IL-1a | 22 | 0 | 2 | 0 |
| Total | 43 | 656 | 11(1.68%) | 19(2.9%) | 141(21.49%) | ||
Abbreviations: Ref, reference□AH: aluminum hydroxide; NI, not identifiable; NR, not Reported; DC, dendritic cells□NDV, newcastle disease virus; IL, interleukin; ß-HCG, ß-human chorionic gonadotropin; THI,tetanustoxoidntigen/hepatitis B/influence matrix peptide; IFA, incompleteFreund's adjuvant.